Saffron vs Ashwagandha: Which Ingredient Is Better for Emotional Wellness Supplements?

Introduction

Emotional wellness is rapidly becoming one of the most commercially important supplement categories of this decade. An estimated 280 million people worldwide live with depression, according to the World Health Organization, and far more experience everyday low mood, stress overload, and poor sleep that never reaches a clinical diagnosis [1]. This enormous “sub-clinical” population is exactly where dietary supplements compete.

Consumer demand has also evolved far beyond simple “stress relief.” Today’s best-selling emotional wellness products are built around more specific positioning territories:

• Mood Support— positive mood, motivation, emotional balance
• Calm Focus— stress resilience without sedation
• Sleep & Recovery— falling asleep faster, waking restored
• Women’s Emotional Wellness— PMS mood, perimenopause, emotional eating
• Burnout & Productivity— energy, cortisol management, mental endurance

The market confirms the opportunity: the global adaptogens market alone was valued at approximately USD 11.51 billion in 2025 and is projected to reach USD 16.32 billion by 2030, growing at a 7.2% CAGR [2].

For brand owners, formulators, and private label buyers, this raises a very practical sourcing question:

Should your next emotional wellness product be formulated with saffron, ashwagandha — or a combination of both?

This guide compares the two ingredients the way an OEM decision-maker actually needs: clinical evidence by application, cost and dosage-form economics, regulatory and claim risk, product positioning fit, and formulation synergy. All clinical claims are referenced to peer-reviewed human studies and official sources listed at the end of this article.

Quick Comparison Summary

Details, evidence, and formulation guidance for each row are covered in the sections below.

Table of Contents

1. Understanding the Two Ingredients
2. Mechanisms of Action: How Do They Support Emotional Wellness?
3. Clinical Evidence Comparison
4. Scientific Evidence Summary Table
5. Market Trends and Consumer Demand
6. Formulation Considerations for Supplement Brands
7. Which Ingredient Fits Different Product Positioning?
8. Why More Brands Are Combining Saffron and Ashwagandha
9. Decision Framework for Brands
10. OEM and Private Label Considerations
11. Partnering with KS Nutripharma
12. Frequently Asked Questions
13. Conclusion
14. References

1. Understanding the Two Ingredients

What Is Saffron Extract?

Saffron extract is derived from the dried stigmas of Crocus sativus L. — the most expensive culinary spice in the world, now increasingly used as a standardized nutraceutical ingredient.

Key bioactive compounds:

• Crocin/crocins— carotenoid pigments responsible for most mood-related activity in modern extracts
• Safranal— the volatile compound behind saffron’s aroma, with additional neuroactive properties
• Picrocrocin— the bitter-tasting precursor of safranal

Common standardized forms on the market:

• Affron® (standardized to >3.5% Lepticrosalides® — crocins + safranal)
• Saffr’Activ® and other crocin-standardized extracts (typically 2–5% crocin)

Primary commercial applications: mood balance, emotional eating support, PMS and women’s emotional wellness, sleep quality, and positive mood/motivation products.

Notably, saffron’s clinically validated dose is remarkably low — most successful human trials use just 28–30 mg per day [3][4], which has major implications for formulation economics discussed later.

What Is Ashwagandha Extract?

Ashwagandha (Withania somnifera (L.) Dunal) is an adaptogenic herb from Ayurvedic tradition, with the root (and sometimes root + leaf) used for modern extracts.

Key bioactive compounds:

• Withanolides— the steroidal lactones used as the standardization marker (commercial extracts range from 1.5% to 35% withanolide content)

Common standardized forms on the market:

• KSM-66® (root-only, full-spectrum, ~5% withanolides)
• Sensoril® (root + leaf, higher withanolide concentration)
• Shoden® (high-potency, 35% withanolide glycosides)

Primary commercial applications: stress reduction, cortisol management, sleep support, athletic recovery, and burnout/energy formulas.

Clinically studied doses are considerably higher than saffron — typically 240–600 mg per day of standardized extract [5][6][7].

2. Mechanisms of Action: How Do They Support Emotional Wellness?

Saffron Mechanisms

Neurotransmitter modulation. Saffron’s crocins and safranal appear to influence serotonergic, dopaminergic, and noradrenergic pathways — including mild serotonin reuptake inhibition — which aligns with its consistently positive results in mood trials [3][8].

Antioxidant and neuroprotective effects. Crocins are potent antioxidants; oxidative stress and neuroinflammation are increasingly linked to mood disturbances, and saffron’s bioactives have shown protective effects in preclinical models [8].

HPA axis and stress response modulation. Trial authors hypothesize that saffron also moderates the physiological stress response, contributing to its combined mood and sleep effects [4].

Ashwagandha Mechanisms

Adaptogenic effects. Ashwagandha is classified as an adaptogen — it helps normalize the body’s response to physical and psychological stressors rather than pushing one pathway in a single direction [9].

Cortisol reduction. Multiple RCTs show significant reductions in serum and morning salivary cortisol versus placebo — ashwagandha’s best-documented mechanism [5][6].

GABAergic activity. Withanolides show GABA-mimetic activity, consistent with ashwagandha’s calming and sleep-supportive effects [7][9].

Stress resilience and recovery. By moderating the hypothalamic–pituitary–adrenal (HPA) axis, ashwagandha supports recovery from chronic stress load — the physiological core of “burnout” positioning [6][9].

Formulator’s takeaway: saffron works primarily on the mood/neurotransmitter side, while ashwagandha works primarily on the stress/cortisol side. This mechanistic complementarity is the scientific foundation for the combination formulas discussed in Section 8.

3. Clinical Evidence Comparison

3.1 Mood Support

Saffron is one of the most clinically studied botanicals for mood. A 2019 systematic review and meta-analysis of randomized controlled trials found saffron supplementation significantly improved symptoms of depression and anxiety versus placebo [3]. The evidence base has kept growing: a 2026 GRADE-assessed meta-analysis of 34 RCTs confirmed significant benefits of saffron on depression, anxiety, and mood outcomes [8].

The largest saffron trial to date — a 2025 randomized, double-blind, placebo-controlled study of 202 adults with low mood published in The Journal of Nutrition — found that 28 mg/day of a standardized saffron extract (Affron®) produced significantly greater improvement in depression scores than placebo, with 72.3% of saffron participants achieving a clinically significant response versus 54.3% on placebo [4].

Ashwagandha’s mood effects are real but secondary: improvements in depression and anxiety scales in ashwagandha trials generally appear as downstream consequences of stress and cortisol reduction rather than as primary mood outcomes [6][10].

3.2 Stress Reduction

This is ashwagandha’s home territory. In the landmark 2012 RCT, 64 adults with chronic stress taking 300 mg of KSM-66® twice daily for 60 days showed a 27.9% reduction in serum cortisol and significant improvements across all stress-assessment scales versus placebo [5]. A 2019 RCT using 240 mg/day of a high-potency extract (Shoden®) again found significantly greater reductions in morning cortisol and anxiety scores versus placebo [6]. A 2022 systematic review and meta-analysis of 12 RCTs concluded that ashwagandha supplementation significantly reduced stress and anxiety measures compared with placebo [10].

Saffron shows moderate stress benefits in trials, but cortisol reduction is not its signature effect [3][4].

3.3 Sleep Support

Both ingredients support sleep — through different routes.

Saffron appears best suited to emotion-linked sleep problems: difficulty unwinding, mood-related sleep quality issues. A 2025 randomized, double-blind, placebo-controlled trial in adults with moderate insomnia found a standardized saffron extract significantly improved sleep quality versus placebo [11], and the 2026 trial in women aged 50–70 found improvements in sleep-related daytime impairment alongside mood benefits [12].

Ashwagandha is best suited to stress-related sleep disturbance: elevated evening cortisol, wired-and-tired presentations. A 2021 systematic review and meta-analysis of five RCTs (400 participants) found ashwagandha extract significantly improved overall sleep versus placebo, with stronger effects at doses ≥600 mg/day and durations ≥8 weeks, and in participants with insomnia [7].

3.4 Women’s Emotional Wellness

This is where saffron clearly differentiates — and where many competitor articles have a content gap.

Saffron advantages: saffron has direct clinical evidence in women’s health applications. A 2026 systematic review and meta-analysis found saffron significantly improved premenstrual syndrome (PMS) and dysmenorrhea outcomes [13]. The 2026 RCT in women aged 50–70 experiencing low mood and poor sleep showed nearly double the clinical response rate of placebo (48.8% vs 25.6%) plus improvements in self-esteem — highly relevant for perimenopause-positioned products [12]. Saffron also has an established research history in emotional eating and snacking behavior.

Ashwagandha opportunities: stress management, fatigue, and stress-related hormonal balance — supportive positioning rather than a core women’s-health claim area [9].

4. Scientific Evidence Summary Table

4.1 Human Clinical Research Comparison

4.2 Evidence Strength Scorecard

4.3 Safety and Responsible Formulation Notes

For B2B buyers, safety and regulatory risk are as important as efficacy:

• Saffron: clinical doses of 28–30 mg/day were well tolerated in trials with no serious adverse events reported [3][4]. Note that saffron at very high gram-level doses is toxic — a non-issue at supplement doses, but identity testing matters because saffron is among the most frequently adulterated botanicals in global trade.
• Ashwagandha:generally well tolerated in trials up to 3 months [9]. The NIH Office of Dietary Supplements advises caution for pregnant women, people with thyroid conditions, and those on sedative, thyroid, or immunosuppressant medications [9]. Rare cases of liver injury have been reported and are catalogued in the NIH LiverTox database [14] — one more reason to specify root-only extracts from audited supply chains and to include appropriate label cautions.

These statements describe ingredient-level research, not finished-product claims. Finished supplements must comply with the regulations of each target market.

5. Market Trends and Consumer Demand

5.1 Ashwagandha Market Trends

Ashwagandha is the anchor ingredient of the adaptogen boom. U.S. retail sales of herbal supplements reached USD 13.2 billion in 2024 (+5.4% year over year), and ashwagandha remained among the top-selling herbs in the American Botanical Council’s HerbalGram Herb Market Report [15]. It also holds the largest share of the adaptogens market by ingredient type [2].

But from a brand-strategy perspective, its success has created three problems:

• Extreme competition: Amazon and retail shelves are saturated with near-identical ashwagandha capsules and gummies.
• Product homogenization: same extract, same dose, same claims — differentiation is increasingly difficult.
• Price pressure: heavy competition on raw material and finished-product pricing compresses margins.

Ashwagandha remains a high-volume, must-stock ingredient — but it rarely wins a premium positioning battle on its own anymore.

5.2 Saffron Market Trends

Saffron extract is emerging as the premium mood ingredient of the emotional wellness category:

• Positioned at the high end of the mood support segment, supported by a growing stack of modern RCTs [4][8].
• Fast-growing from a smaller base, with strong social media momentum (“saffron for mood” content performs exceptionally well on TikTok and Instagram).
• Large differentiation headroom: far fewer competing SKUs than ashwagandha, with clinically branded extracts enabling premium storytelling.
• The low 28–30 mg clinical dose fits modern delivery formats — gummies, stick packs, and functional beverages — where space and taste are at a premium.

5.3 Consumer Product Trend Snapshot

5.4 What Consumers Actually Say

Real-world consumer language matters for positioning and copywriting. Aggregated from recurring themes in Amazon reviews and Reddit communities (r/Supplements, r/Biohackers, r/StackAdvice), the most frequently reported experiences are:

Ashwagandha users most often report:

• Feeling less stressed and “more even” during the workday
• Falling asleep more easily and waking more rested
• A general sense of calm without feeling sedated

Saffron users most often report:

• Feeling “happier,” more positive, and more motivated
• Reduced emotional or stress-driven snacking
• Improved mood around the menstrual cycle

The pattern mirrors the clinical evidence almost exactly: consumers reach for ashwagandha to dial stress down, and for saffron to lift mood up. Products that promise both need both.

5.5 Consumer Search Intent Comparison

Ashwagandha-related searches cluster around: stress relief, cortisol support, ashwagandha gummies, sleep gummies.

Saffron-related searches cluster around: mood support, “happy pills,” emotional eating, saffron for PMS, natural mood support alternatives.

For SEO-driven brands, the two ingredients attract different customer avatars — another argument for treating them as complementary portfolio ingredients rather than either/or competitors.

6. Formulation Considerations for Supplement Brands

6.1 Cost and Label Economics

A common buyer mistake is comparing the two on cost per kilogram. What matters is cost per clinically effective dose: saffron’s 28–30 mg clinical dose means even premium standardized extracts add a manageable cost per unit — while supporting a significantly higher retail price point [3][4].

6.2 Stability and Dosage Form Compatibility

Saffron works well in:

• Capsules and tablets
• Gummies (low dose fits easily; flavor pairs well with berry/citrus profiles)
• Stick packs and powder blends
• Functional beverages and shots (water-dispersible crocin grades available)

Ashwagandha works well in:

• Capsules and tablets
• Gummies (requires taste-masking strategy)
• Powders and drink mixes

Formulation cautions for ashwagandha: its characteristic bitter-earthy taste requires flavor work in gummies and beverages, and a 300–600 mg dose occupies significant formula space in multi-ingredient products. Microencapsulation and taste-masking technologies can solve both issues — discuss options with your contract manufacturing partner.

6.3 Regulatory and Claim Considerations

United States. Both ingredients are marketed as dietary supplements under DSHEA. Structure/function claims do not require pre-approval but must be truthful, substantiated, notified to the FDA within 30 days of marketing, and accompanied by the mandatory disclaimer; disease treatment claims are prohibited [16].

Compliant claim directions include:

• ✔ “Supports emotional well-being”
• ✔ “Helps maintain a positive mood”
• ✔ “Helps the body adapt to stress”
• ✔ “Supports relaxation and restful sleep”
• ✘ “Treats depression” / “Cures anxiety” / “Antidepressant alternative” — prohibited disease claims

6.4 Regulatory Watch (2026): What Procurement Teams Need to Know

Ashwagandha faces a fragmented and tightening regulatory landscape, documented in a 2025 peer-reviewed review of adaptogenic botanicals [17]:

• Denmark: the Danish Veterinary and Food Administration banned ashwagandha in food supplements in April 2023, following a 2020 risk assessment by the Technical University of Denmark (DTU) that cited thyroid, reproductive, and CNS concerns; the ban remains in force [17].
• United Kingdom: the Food Standards Agency ran a formal call for evidence in 2024 to inform a UK risk assessment; no ban is in place, but dose guidance or labeling requirements remain possible [17].
• France: ANSES issued a precautionary warning in 2024 advising vulnerable groups (pregnant women, minors, people with thyroid or liver conditions) to avoid ashwagandha [17].
• Poland: took a dose-limit approach rather than a ban (root powder max 3 g/day; standardized extracts limited) [17].
• Sweden and Finlandhave evaluated following Denmark’s approach [17].

Practical implication: for EU-destined products, specify root-only, fully documented standardized extracts, include conservative label cautions, and confirm country-by-country status before launch.

Saffron currently carries a materially lower regulatory risk profile, with broad acceptance in both US and EU supplement markets and no comparable national restrictions [17].

Brands should validate final label claims with regulatory counsel for each destination market — your manufacturing partner should be able to support multi-market compliance documentation.

7. Which Ingredient Fits Different Product Positioning?

7.1 Best Use Cases for Saffron

• Premium mood products— flagship mood SKUs with branded, clinically studied extracts
• Women’s emotional wellness— PMS mood, perimenopause support, self-esteem-adjacent positioning [12][13]
• Emotional eating support— a defensible niche with direct research history
• “Happy mood” gummies— the strongest trend-fit format; see our mood support supplement manufacturing solutions

7.2 Best Use Cases for Ashwagandha

• Stress support formulas— the category default with the deepest evidence base [5][10]
• Sleep products— particularly stress-related sleep disturbance [7]; explore our sleep support supplement capabilities
• Sports recovery products— cortisol and recovery positioning for active consumers
• Burnout and productivity supplements— the fastest-growing stress sub-niche; see our stress relief supplement solutions and dedicated ashwagandha supplement manufacturing programs

8. Why More Brands Are Combining Saffron and Ashwagandha

This is the highest-conversion section for OEM inquiries — and the smartest product strategy for most brands.

8.1 Synergistic Formulation Logic

The two ingredients cover complementary pathways:

• Saffron drives: positive mood, emotional balance, motivation
• Ashwagandha drives: stress reduction, cortisol management, relaxation

Together they form a “Mood + Stress Dual-Pathway Formula” — one product that addresses both how the consumer feels and how their body handles stress. This dual positioning also widens the claim set, the keyword footprint, and the customer avatar, while making copycat competition harder.

8.2 OEM Formula Cards

Formula 1 — Daily Emotional Balance Capsules

• Key Ingredients: Saffron extract (standardized, Affron®-type) 28 mg • KSM-66® Ashwagandha 300 mg • Magnesium glycinate 100 mg • Vitamin B6 5 mg
• Positioning: Daily mood + stress maintenance • Calm productivity
• Suggested Formats: Capsules  Tablets
• Market Opportunity: Core daily-use SKU for the fast-growing mood + stress dual-benefit segment [2]
• OEM Support: Private label • Custom dosing • Vegetarian capsules • Full label compliance review

Formula 2 — Women’s Emotional Wellness Gummies

• Key Ingredients:Saffron extract 30 mg • L-Theanine 200 mg • Vitamin D3 1,000 IU • B-complex blend
• Positioning:PMS mood • Perimenopause • Emotional balance [12][13]
• Suggested Formats: Gummies  Stick packs
• Market Opportunity: Growing demand in women’s healthy-aging and cycle-support supplements — saffron is the strongest-evidence botanical in this space [13]
• OEM Support: Private label • Custom flavors • Sugar-free and vegan pectin options

Formula 3 — Stress Recovery Drink Mix

• Key Ingredients: Ashwagandha root extract 300 mg • Saffron extract 28 mg • L-Theanine 200 mg • Rhodiola extract (3% rosavins) 200 mg
• Positioning:Burnout recovery • Evening wind-down • Cortisol support [5][6]
• Suggested Formats: Stick packs • Powder blends  Functional liquid shots
• Market Opportunity: Premium recovery-positioned line extension for stress and sleep brands [7]
• OEM Support: Custom flavor systems • Taste-masked ashwagandha • Single-serve stick pack filling

Formula cards are illustrative starting points; final formulas require stability, compatibility, and regulatory review for your target markets.

9. Decision Framework for Brands

A 60-second selector for your next product brief:

Choose Saffron if:

• ✓ Premium pricing strategy (USD 30+ retail)
• ✓ Women’s emotional wellness positioning
• ✓ Mood-focused, “feel-good” product promise
• ✓ Gummies, stick packs, or functional beverages

Choose Ashwagandha if:

• ✓ Stress and cortisol formulas
• ✓ Sleep-support products
• ✓ Sports recovery and performance lines
• ✓ Mass-market, high-volume SKUs

Choose Both if:

• ✓ Comprehensive emotional wellness positioning
• ✓ Premium flagship product development
• ✓ Multi-benefit formulations (mood + stress + sleep)
• ✓ You need defensible differentiation against copycat listings

10. OEM and Private Label Considerations

10.1 Choosing the Right Ingredient Supplier

When briefing your OEM/ODM partner, specify:

• Standardization: saffron — crocin % and safranal %; ashwagandha — withanolides % and plant part used (root-only vs root + leaf)
• Clinical backing: prefer extracts with human RCTs on the specific ingredient, not just the botanical species
• Identity testing: saffron is a high-adulteration-risk botanical; DNA/HPTLC fingerprinting is best practice for ashwagandha as well
• Contaminant control: heavy metals, pesticides, microbiology — batch-by-batch COAs
• Supply chain traceability: origin documentation, stable multi-origin sourcing, and inventory continuity

Our quality control and testing framework covers identity, potency, heavy metals, pesticides, and microbiological testing across every production batch.

10.2 Product Format Opportunities

Both ingredients — alone or combined — can be delivered in:

• Capsules (including capsule-in-capsule technology) and tablets
• Gummies (pectin, gelatin, vegan, sugar-free options)
• Powders and stick packs
• Functional liquids and mood shots

11. Partnering with KS Nutripharma

KS Nutripharma is a one-stop nutraceutical contract manufacturer serving 500+ brands across 60+ export regions since 2007, with end-to-end OEM, ODM, and private label services from formulation development to finished-product delivery.

• OEM Available: Yes — full OEM / ODM / private label support, from custom formulation to shelf-ready packaging
• MOQ: Low MOQ with flexible pilot-batch programs for market testing, scaling to full commercial volumes
• Lead Time: Fast-launch programs available; production timelines confirmed per project at quotation
• Certifications: cGMP-certified manufacturing, ISO, HACCP, Kosher, and Halal certifications
• Dosage Forms & Daily Capacity: Hard capsules 5+ million/day, softgels 2+ million/day, tablets 12+ million/day, gummies 2+ million/day, plus powders/stick packs (5,000 tons/year) and liquids/shots (3,000 tons/year) — see full manufacturing capacity
• Request Quote: Contact our team for formulation proposals, samples, and quotations

For ingredient-level sourcing, our plant extract division supplies standardized botanical extracts, including ashwagandha extract, with ISO9001, ISO22000, HACCP, Kosher, and Halal certifications and US/EU warehouse stock.

Free resource for brands: request our Emotional Wellness Ingredient Comparison sheet — including dosage tables, market trends, formulation recommendations, and an OEM briefing checklist — via the contact page.

12. Frequently Asked Questions

Is saffron better than ashwagandha for mood support?

For mood-specific outcomes, yes — current evidence favors saffron. Multiple meta-analyses and the largest saffron RCT to date (202 adults) show significant mood benefits at just 28–30 mg/day [3][4][8]. Ashwagandha improves mood mainly as a secondary effect of stress reduction [10].

Can saffron and ashwagandha be combined?

Yes. The two ingredients work through complementary mechanisms (neurotransmitter/mood vs HPA-axis/cortisol), and no adverse interactions have been reported at standard supplemental doses. Combination “mood + stress” formulas are one of the fastest-growing product architectures in the category — see Section 8 for example formula cards.

Which ingredient has stronger evidence for stress management?

Ashwagandha. Its stress and cortisol evidence base includes multiple RCTs and meta-analyses, with cortisol reductions of up to 27.9% reported in a 60-day trial [5][6][10].

Which ingredient is more suitable for women’s wellness products?

Saffron. It has direct clinical evidence for PMS symptoms, perimenopausal low mood, and emotional eating [12][13], whereas ashwagandha’s women’s-health evidence remains limited [9].

Which ingredient offers better product differentiation?

Saffron, currently. Ashwagandha is a high-volume essential with severe SKU saturation; saffron offers premium positioning, lower competition, strong social media momentum, and a compelling clinical story at a low per-unit dosage cost.

Is ashwagandha still safe to use in supplements sold in Europe?

Ashwagandha remains legal in most European markets, but Denmark banned it in supplements in 2023 and several countries have issued warnings or dose limits [17]. For EU-destined products, use root-only standardized extracts with full documentation, conservative label cautions, and country-by-country regulatory confirmation.

13. Conclusion

Saffron vs. Ashwagandha: There Is No Universal Winner

The right answer depends on your product positioning, target avatar, and price architecture:

Choose saffron if you want: premium positioning, clinically backed mood enhancement at a low 28–30 mg dose, women’s wellness differentiation, and a defensible, less crowded shelf space.

Choose ashwagandha if you want: mass-market stress and cortisol support, sleep and recovery formulas, sports nutrition positioning, and proven, high-volume consumer recognition.

Combine both if you want: a comprehensive “Mood + Stress Dual-Pathway” emotional wellness product with higher perceived value, broader claim coverage, and stronger differentiation against copycat competition.

Ready to Develop an Emotional Wellness Supplement?

KS Nutripharma supports:

• ✓ Saffron gummies and mood-support products
• ✓ Ashwagandha capsules, tablets, and powders
• ✓ Mood & stress combination formulas
• ✓ Women’s emotional wellness products
• ✓ Functional stick packs and liquid shots
• ✓ Low MOQ pilot production for market testing

Request today: formula suggestions • samples • cost estimates • regulatory documentation — via our Request Quote page. Our formulation team will help you select the right ingredient strategy, dosage form, and claim set for your target market.

Related Resources

• Mood Support Supplement Manufacturing
• Stress Relief Supplement Manufacturing
• Sleep Support Supplement Manufacturing
• Ashwagandha Supplement Manufacturing
• Gummy Supplement Manufacturing
• Capsule-in-Capsule Technology
• Powder & Stick Pack Manufacturing
• Manufacturing Capacity Overview
• Quality Control & Testing

This article was prepared by the KS Nutripharma content team and reviewed by our formulation scientists and regulatory affairs specialists.

Disclaimer: This article is intended for B2B industry readers and is for informational purposes only. It summarizes ingredient-level scientific research and does not constitute medical advice, finished-product claims, or regulatory guidance. These statements have not been evaluated by the Food and Drug Administration. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. Brands should validate all formulations and label claims with qualified regulatory counsel for each target market.

14. References

1. World Health Organization. Depression (Fact Sheet). https://www.who.int/news-room/fact-sheets/detail/depression
2. Grand View Research. Adaptogens Market Size & Share Report, 2025–2030. https://www.grandviewresearch.com/industry-analysis/adaptogens-market-report
3. Marx W, Lane M, Rocks T, et al. Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis. Nutrition Reviews. 2019;77(8):557–571. https://pubmed.ncbi.nlm.nih.gov/31135916/
4. Lopresti AL, Smith SJ, Marx W, Díez-Municio M, Morán-Valero MI. An Examination into the Effects of a Saffron Extract (Affron) on Mood and General Wellbeing in Adults Experiencing Low Mood: A Randomized, Double-Blind, Placebo-Controlled Trial. The Journal of Nutrition. 2025. https://pubmed.ncbi.nlm.nih.gov/40414301/
5. Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian Journal of Psychological Medicine. 2012;34(3):255–262. https://pubmed.ncbi.nlm.nih.gov/23439798/
6. Lopresti AL, Smith SJ, Malvi H, Kodgule R. An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: A randomized, double-blind, placebo-controlled study. Medicine. 2019;98(37):e17186. https://pubmed.ncbi.nlm.nih.gov/31517876/
7. Cheah KL, Norhayati MN, Husniati Yaacob L, Abdul Rahman R. Effect of Ashwagandha (Withania somnifera) extract on sleep: A systematic review and meta-analysis. PLoS ONE. 2021;16(9):e0257843. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0257843
8. Effect of saffron on depression, anxiety and mood disorder: a GRADE assessed systematic review and meta-analysis of 34 randomized controlled trials. Nutritional Neuroscience. 2026. https://pubmed.ncbi.nlm.nih.gov/41693488/
9. National Institutes of Health, Office of Dietary Supplements. Ashwagandha: Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/Ashwagandha-HealthProfessional/
10. Akhgarjand C, Asoudeh F, Bagheri A, et al. Does Ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A systematic review and meta-analysis of randomized controlled trials. Phytotherapy Research. 2022;36(11):3967–3978. https://pubmed.ncbi.nlm.nih.gov/36017529/
11. Effect of a saffron extract on sleep quality in adults with moderate insomnia: A decentralized, randomized, double-blind, placebo-controlled trial. Sleep Medicine: X. 2025. https://pubmed.ncbi.nlm.nih.gov/40698027/
12. Lopresti AL, et al. The effects of a saffron extract (Affron®) on mood, sleep, self-esteem, and exploratory measures of physical appearance in women aged 50 to 70 years experiencing low mood and poor sleep: a randomised, double-blind, placebo-controlled trial. Frontiers in Nutrition. 2026. https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2026.1838513/full
13. Effect of saffron on premenstrual syndrome and dysmenorrhea: a systematic review and meta-analysis. Korean Journal of Family Medicine. 2026. https://pubmed.ncbi.nlm.nih.gov/41151539/
14. National Institutes of Health. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury — Ashwagandha. https://www.ncbi.nlm.nih.gov/books/NBK548536/
15. Smith T, Lang C, Craft E. US Sales of Herbal Supplements Increased by 5.4% in 2024. HerbalGram(American Botanical Council) Herb Market Report, Issue 144. 2025. https://www.herbalgram.org/news/press-releases/2025/us-sales-herbal-supplements-2024-increase/
16. S. Food and Drug Administration. Structure/Function Claims. https://www.fda.gov/food/food-labeling-nutrition/structurefunction-claims
17. Panossian A, Lemerond T. Two Sides of the Same Coin for Health: Adaptogenic Botanicals as Nutraceuticals for Nutrition and Pharmaceuticals in Medicine. Pharmaceuticals. 2025;18(9):1346. https://www.mdpi.com/1424-8247/18/9/1346